Mathias come to Forbion from Novo Ventures, which he joined in 2016.
At Novo, he led due diligence on a dozen biotech companies across Europe, including success stories such as Yellow Jersey Therapeutics (Numab), which was acquired by Johnson and Johnson, Therachon, which was acquired by Pfizer and NBE Therapeutics, which was bought by Boehringer Ingelheim as well as four NASDAQ IPO: VectivBio, Inventiva, Pharvaris and Lava Therapeutics.
Moreover, he has supported several Novo Ventures portfolio companies operationally with their corporate and reimbursement strategies, refinancing, business development and exit trajectories. Mathias holds a PhD in Nanomedicine with an emphasis on Immunotherapy and Drug Delivery from Aarhus University. During his education, Mathias also studied at Berkeley and Harvard Medical School.
It’s a true honor to work at Forbion alongside passionate colleagues, equally dedicated to transforming innovative science into new therapies that benefit patients worldwide.
Portfolio
Companies worked on by Mathias Vinther
